前立腺癌に対するEstramustine phosphate disodium(Estracyt)の治療効果について --臨床成績とヌードマウス移植腫瘍に対する抗腫瘍効果の検討--

Abstract

Effectiveness of Estracyt for carcinoma of the prostate was studied both clinically and experimentally. The drug was administrated to 13 patients, 4 untreated and 9 relapsed cases from the previous endocrine manipulation. All of the former (100%) and 2 of the latter cases (22%), i.e. 6 of 13 cases (46%) in total, responded well to this therapy. It may be postulated that effect of Estracyt depends not only on estrogenic but also on cytotoxic activity as well, judged from marked degenerative figures on histological examination of the biopsy specimen, which has never been experienced through routine estrogen therapy. Although Estracyt did not show a significant reduction of the tumor size in nude mice, which had been obtained by injection of cultured cells established from a human prostatic cancer tissue, remarkable degeneration was observed on histological examination.